Strategic Memo: Navigating the Paradigm Shift of AI in Pharmaceutical Development and Pricing.

The use of artificial intelligence is no longer a future scenario, but an active force that is fundamentally dismantling the industry’s traditional profit models. This paper highlights the urgent strategic choices now confronting us, as AI erodes established barriers to entry, dramatically compresses development timelines, and directly shortens the windows for achieving profitability.

The Strategic Imperative

We are now witnessing an entirely new velocity across the pharmaceutical value chain. From early discovery to regulatory submission, AI is no longer a tool for incremental improvement, but a disruptive force that is hollowing out traditional sources of competitive advantage.

In this e-book, we analyze three decisive shifts:

• The erosion of exclusivity: How accelerated development by competitors is shrinking the period of uncontested market profitability.
• The pricing paradox: The central tension between sustaining higher prices to rapidly recoup R&D investments and leveraging efficiency gains to reduce costs.
• Global pressures: How regulatory bottlenecks and global price disparities complicate the realization of AI’s full potential.